Last edition
News about "RenNano platform"
Biocytogen Signs Non-Exclusive VHH Antibody Licensing Deal with Qilu Pharmaceutical
Biocytogen grants Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule developed through its RenNano platform to support neuroscience drug research.
RenNano Platform | 04/09/2026 | By News Bureau | 118
Biocytogen Grants Licence for RenNano Platform to Taisho Pharmaceutical
Biocytogen licenses its RenNano platform to Taisho Pharmaceutical to advance fully human heavy chain-only antibody discovery, supporting in-vivo screening and downstream research.
RenNano Platform | 31/03/2026 | By News Bureau | 192
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy